Jia Zipu, Shrestha Niti, Wang Shuo, Zhao Chunmei, Wang Tao, Luo Fang
Department of Day Surgery Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
J Pain Res. 2025 Jan 15;18:217-227. doi: 10.2147/JPR.S497029. eCollection 2025.
Scalp nerve blocks (SNB) may significantly reduce post-craniotomy pain (PCP) but only for a short period of time. Dexamethasone, as an adjuvant to local anesthetics, was reported to prolong the analgesia duration of never block; however, the addition of dexamethasone to SNB is rare. We therefore tested the hypothesis that dexamethasone as an adjuvant to bupivacaine in SNB is positive after craniotomy.
Patients elective for craniotomy were randomly assigned to receive SNB with bupivacaine alone compared with dexamethasone and bupivacaine. The primary outcome was the duration of analgesia. The secondary outcomes include the cumulative amount of sufentanil consumption, the numeric rating scale (NRS), patient satisfaction score (PSS), the complications during the postoperative period, and SNB's relevant adverse events.
There were 156 subjects included and 78 patients in each group (control and DEX group). The analgesia duration was significantly prolonged in the DEX group compared with the control group (660min (390,1005) vs 420min (314,504)) (p<0.001). The postoperative sufentanil consumption was lower in the DEX group compared with the control group at 12h (P<0.001), 24h (P=0.014), and 48h (P=0.049). The NRS scores were significantly lower in the DEX group compared with the control group at 8h (P<0.001) and 12h (P=0.007) after craniotomy. From 4h to 16h postoperative, the PSS in the control group was lower than the DEX group (P < 0.05).
Perineural dexamethasone as an adjuvant to bupivacaine without background glucocorticoid has the potential to improve the postoperative analgesic effect and patients' satisfaction without serious complications after craniotomy.
头皮神经阻滞(SNB)可显著减轻开颅术后疼痛(PCP),但仅能维持较短时间。据报道,地塞米松作为局部麻醉药的辅助剂,可延长神经阻滞的镇痛时间;然而,在SNB中添加地塞米松的情况较为罕见。因此,我们检验了以下假设:在开颅术后,地塞米松作为布比卡因的辅助剂用于SNB具有积极作用。
将择期行开颅手术的患者随机分为两组,分别接受单纯布比卡因的SNB和布比卡因联合地塞米松的SNB。主要结局指标为镇痛持续时间。次要结局指标包括舒芬太尼的累计用量、数字评分量表(NRS)、患者满意度评分(PSS)、术后并发症以及SNB相关不良事件。
共纳入156例受试者,每组78例(对照组和DEX组)。与对照组相比,DEX组的镇痛持续时间显著延长(660分钟(390,1005)对420分钟(314,504))(p<0.001)。DEX组术后12小时(P<0.001)、24小时(P=0.014)和48小时(P=0.049)的舒芬太尼用量低于对照组。开颅术后8小时(P<0.001)和12小时(P=0.007),DEX组的NRS评分显著低于对照组。术后4小时至16小时,对照组的PSS低于DEX组(P<0.05)。
在无糖皮质激素背景下,神经周围注射地塞米松作为布比卡因的辅助剂,有可能改善开颅术后的镇痛效果和患者满意度,且无严重并发症。